Marion County Multiple Sclerosis Self-Help Group, Ocala, Florida

Enjoying Life One Day at a Time!

Current Trials in Florida

1 Recruiting Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Fingolimod;   Drug: Fingolimod;   Drug: Fingolimod matching placebo
2 Recruiting Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: BG00012
3 Recruiting Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Interferon beta 1-a;   Drug: glatiramer acetate;   Other: placebo
4 Recruiting Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: alemtuzumab;   Biological: alemtuzumab;   Biological: interferon beta-1a (Rebif®)
5 Recruiting Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: alemtuzumab;   Biological: interferon beta-1a (Rebif®)
6 Recruiting Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: BG00012
7 Recruiting Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
Condition: Secondary Progressive Multiple Sclerosis
Interventions: Drug: natalizumab;   Other: standard of care
8 Recruiting 12-Week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients
Condition: Multiple Sclerosis
Interventions: Drug: CS-0777 tablets;   Drug: CS-0777 tablets;   Drug: CS-0777 tablets;   Drug: CS-0777 matching placebo tablets
9 Recruiting Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323
Condition: Multiple Sclerosis
Interventions: Drug: CDP323;   Drug: placebo;   Drug: CDP323
10 Recruiting A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: interferon beta-1a;   Drug: methylprednisolone;   Drug: ocrelizumab;   Drug: placebo
11 Recruiting Observational Study to Determine Impact of Multiple NAb Tests on Treatment Patterns Compared to the Usual Care of MS Patients Receiving High-Dose IFN Therapy.
Condition: Multiple Sclerosis
Intervention: Procedure: NAbs testing
12 Recruiting Evaluation of Natalizumab for thE Relief of MS Associated FatiGue
Condition: Multiple Sclerosis
Intervention:
13 Recruiting BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon â-1a (Avonex®)
Condition: Multiple Sclerosis
Interventions: Drug: laquinimod;   Drug: placebo;   Drug: Interferon â-1a (Avonex®)
14 Recruiting Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
Condition: Pseudobulbar Affect (PBA)
Intervention: Drug: AVP-923